Melanotan-2: Risks & Legal Status

Critical Safety Information#

Melanotan-2 is a research compound that has not been approved for human use by any major regulatory agency. This page provides risk information for educational purposes only.

Growth Factor and Angiogenesis Risks#

Overview Melanotan‑2 (MT‑II) is a potent, non‑selective melanocortin receptor agonist developed as an α‑MSH analogue. Reported safety risks cluster in three domains: potential growth‑factor/tumor‑promotion concerns; immune modulation (including mast‑cell/histamine–mediated reactions); and quality‑control hazards from unregulated peptide sourcing. Evidence is strongest for case‑based associations with melanocytic lesion changes and for substantial product quality variability; mechanistic and animal data support immune effects and provide biological plausibility for tumor‑promoting or immune‑evasive effects.

Growth‑factor and tumor‑promotion concerns • Case signals: Multiple case reports describe melanoma or melanoma in situ temporally associated with MT‑II use, sometimes after short exposures, including a 20‑year‑old who developed melanoma after three weeks of MT‑II with sunbed use, and a 66‑year‑old with melanoma in situ four weeks after initiating MT‑II from a compounding pharmacy. Additional reports document eruptive and dysplastic melanocytic nevi emerging or evolving during melanotan use. Reviews summarizing chronic MC1R activation also cite eruptive nevi and multiple melanomas in high‑risk genotypes despite melanocortin analogue exposure. • Mechanistic plausibility: MT‑II agonizes MC1R on melanocytes, intensifying melanogenesis and altering cell morphology; α‑MSH/MC1R signaling intersects with cAMP/MITF pathways that regulate pigmentation and can influence proliferation. Case‑based reviews further note α‑MSH’s anti‑inflammatory actions that may reduce T‑cell interactions with melanoma cells, potentially aiding immune evasion. While causality is unproven and some in vitro data are conflicting, the convergence of case signals with plausible receptor‑level biology supports caution regarding growth‑factor–like effects on melanocytic lesions.

Immune modulation and hypersensitivity risks • Anti‑inflammatory/immunomodulatory signaling: Melanocortin peptides exert glucocorticoid‑independent anti‑inflammatory effects across immune cells (MC1/MC3/MC5 on neutrophils, monocytes, dendritic cells, B/T cells), implying potential to blunt inflammatory responses and tumor immune surveillance. Case‑based discussion highlights α‑MSH reducing TNF‑α and T‑cell interactions with melanoma cells, which could theoretically facilitate tumor escape, though direct infection‑risk data in MT‑II users are lacking. • Mast‑cell activation and histamine release: In mice, MT‑II activates mast cells, markedly elevates plasma histamine, and induces hypothermia via H1 receptors; these effects are abolished in mast‑cell–deficient animals and attenuated by H1 blockade, indicating a clear potential for hypersensitivity‑type reactions and route‑dependent systemic effects. These findings align with reports of local injection‑site reactions with melanocortin agonists and support vigilance for urticaria, flushing, hypotension, or other histamine‑mediated events.

Peptide sourcing and quality‑control hazards • Impurity and potency variability: LC‑UV‑MS/MS analysis of illicit online MT‑II vials found wide under‑filling/under‑strength relative to 10‑mg claims (measured 4.32–8.84 mg) and quantifiable impurities of 4.1–5.9%, with inconsistent labeling and unmarked vials, indicating lack of manufacturing controls and dose predictability. Methodological notes emphasize possible undetected co‑eluting impurities and no assessment of residual solvents or salts, adding uncertainty to contaminant profiles. • Contamination, sterility, and misbranding: Investigators documented damaged vial seals, non‑pharmaceutical packaging, and distribution with ancillary supplies ("bacteriostatic water," wipes), raising sterility concerns; regulators have issued warnings and enforcement actions against illegal melanotan products, including reports of microbial contamination in supplied diluent water and advisories that these are unapproved, unsafe products.

Conclusions

• Growth‑factor concerns: Case reports and series link MT‑II exposure with eruptive/dysplastic nevi and melanomas; combined with plausible MC1R/cAMP biology and α‑MSH–mediated immune effects, this supports a credible risk that MT‑II may promote melanocytic lesion growth or unmask/progress susceptible lesions, though causality is not definitively established.
• Immune modulation risks: Melanocortin signaling is broadly anti‑inflammatory and immunomodulatory and MT‑II can activate mast cells with histamine release in vivo, implying risks of hypersensitivity reactions and a theoretical risk of blunted tumor surveillance or infection susceptibility; direct human infection‑risk data specific to MT‑II remain limited.
• Quality control: Illicit/nonregulated MT‑II shows significant potency variability, organic impurities, labeling/packaging defects, and documented contamination of supplied diluents, collectively posing dosing unpredictability, toxicant exposure, and sterility risks.

Quality Control and Sourcing#

Overall context: MT‑II is a potent, non‑selective melanocortin agonist sold through unregulated channels. Reports link use to rapid changes in melanocytic nevi and rare melanomas, and to injection‑related harms typical of image/performance‑enhancing drug (IPED) practices. Regulators have warned against Melanotan products.

• Pregnancy: Highest risk due to absence of safety data and unlicensed status; regulators warn against Melanotan products. Unregulated sourcing and unknown purity further elevate risk. Avoid in pregnancy and lactation.

• Cancer patients (especially melanoma or with numerous/dysplastic nevi): Highest risk because MT‑II/α‑MSH agonism stimulates melanocytes (MC1R), can darken/alter nevi, and has immunomodulatory effects that could reduce immune surveillance. Multiple case reports describe eruptive/dysplastic nevi and melanoma in temporal association with MT use, including melanoma in‑situ shortly after MT‑II initiation. Strongly avoid in patients with prior melanoma or dysplastic nevus syndrome; prompt dermatologic evaluation if lesions change.

• Immunocompromised individuals: High risk due to injection‑related infection hazards and unregulated products. IPED cohorts show elevated prevalence of blood‑borne viruses (HIV, HCV), equipment sharing, abscesses, and product adulteration/contamination. MT‑II/α‑MSH pathways also exert anti‑inflammatory/immunomodulatory effects that could diminish tumor/immune surveillance. Avoid use; if exposed, screen for BBVs and manage injection‑site complications promptly.

• Individuals on anticoagulants: High risk from repeated subcutaneous injections causing bruising/hematoma and from potential abscesses or severe local tissue injury reported after MT‑II; anticoagulation magnifies bleeding complications. Avoid elective MT‑II injections while anticoagulated; if exposure occurs, seek clinical oversight and monitor closely for bleeding.

Key mechanistic and safety signals:

• Melanocortin/α‑MSH agonism is mitogenic for melanocytes and alters nevi; reports link MT use with eruptive nevi and melanoma, with plausible immune‑evasion effects.
• Unregulated supply and self‑injection create contamination, dosing‑purity, and infection risks typical of IPED use; regulators have issued warnings against Melanotan products.

Embedded summary table:

Regulatory and Legal Status#

Question and scope We summarize the regulatory and legal status of Melanotan‑2 (MT‑II) across major jurisdictions, drawing on accessible evidence in our corpus. Where explicit primary-agency links were not captured, we report what the compiled evidence states and note the limitation.

United States (FDA) MT‑II is not FDA‑approved. FDA issued a consumer warning titled “FDA Warns About Unapproved Product, Melanotan II” (2007) and later a 2009 warning letter to an online supplier, treating MT‑II as an unapproved “new drug”; marketing/sale for human use is unlawful absent approval.

United Kingdom (MHRA) MHRA described the “tan jab” as “an unlicensed medicine and may not be safe” (press release, 2008), and UK enforcement targets sale/supply of unlicensed medicines such as MT‑II.

European Union/Europe (EMA and national agencies) There is no evidence of EMA authorization for MT‑II in the accessible materials. Multiple EU/EEA national regulators have warned MT‑II is unlicensed/unauthorized: Danish Medicines Agency (2008), Norwegian Medicines Agency (2007), Swedish Medical Products Agency (2010), and the Irish Medicines Board explicitly: “Melanotan is not authorised in Ireland,” with contamination concerns reported. Collectively, the evidence indicates MT‑II lacks EU authorization and national agencies consider it an unauthorised medicinal product.

Australia (TGA) The corpus includes secondary summaries noting Australian regulators warn consumers and that sale/supply for human use is illegal in Australia; a formal TGA posting was not captured in our evidence set. A TGA spokesperson caution is referenced; thus, MT‑II should be regarded as an unapproved/illegal supply for human use in Australia per these summaries.

Canada (Health Canada) No explicit Health Canada advisory was captured in the retrieved materials. The compilations characterize MT‑II as unapproved/unauthorized across North America; however, we cannot cite a specific Health Canada notice from this corpus. Based on the overall pattern and Canadian alignment with US/EU on unauthorised injectable products sold online, MT‑II is not authorized for sale; explicit Canadian enforcement advisories were not available in our evidence.

Recent regulatory changes Within the accessible 2024 compiled summaries, no recent (post‑2010) approvals or regulatory relaxations for MT‑II were identified. The consistent position across jurisdictions remains that MT‑II is unapproved/unauthorized, with warnings against use and enforcement against sale/supply for human use.

Practical legal implications across jurisdictions

• Not approved/authorized as a medicine; sale/marketing for human use is unlawful without authorization (US “new drug” framework; UK “unlicensed medicine”; EU national “unauthorised medicinal product”).
• Agencies warn of safety and quality risks, including contamination of internet-sold products (Irish Medicines Board contamination warning).

Limitations Our corpus did not retrieve primary URLs from EMA, TGA, or Health Canada; conclusions for these are based on compiled summaries quoting or characterizing those agencies’ positions. No evidence of recent regulatory changes was captured; if such changes occurred very recently, they would not be reflected here.

At-Risk Populations#

Populations at highest risk when using Melanotan‑2 (MT‑II)

Risk Mitigation#

For Researchers#

1. Use only from verified, third-party tested sources
2. Follow proper handling and sterility protocols
3. Document all observations carefully
4. Report adverse events

General Precautions#

1. Consult healthcare providers before any use
2. Start with lowest suggested amounts in research protocols
3. Monitor for any adverse effects
4. Discontinue immediately if problems arise

Related Reading#

• Melanotan-2 overview and research guide
• Melanotan-2 side effects profile
• Melanotan-2 research evidence